ANZCTR search results

To better understand the role played by fat as a food ingredient in decreasing the rate at which a given foods' carbohydrate component is digested and absorbed into the blood stream in the form of glucose.

The primary purpose of the study is to determine whether measurement of total and free cortisol by mass spectrometry improves the diagnostic accuracy of synacthen tests to assess adrenal function in patients with pituitary disease.

The prevalence of overweight/obesity is currently exploding with over 60% of Australian adults in this category, leading to a rapid increase in diabetes, hypertension, and cardiovascular disease (CVD). There is evidence that adding fibre to the diet can improve cardiovascular and diabetes related risk factors although there is little research on fibre consumed as a supplement with both a normal diet and a healty diet.

Determining which types of proteins are effective in lowering glucose response, promoting a greater insulin response and satiety postprandially (after a meal is consumed) has obvious benefits. There is little conclusive evidence on the postprandial effect of different types of proteins on such metabolic factors and satiety in humans. This study aims to determine the satiety and metabolic responses in relation to glycaemia and insulinaemia of four completely different protein sources, namely fish, poultry, dairy (whey) and egg albumin in healthy men aged between 18 and 30 years.

In people with chronic low back pain, a randomised controlled trial comparing the effect of a six week clinical pilates program with a general exercise program on back function with a 3 and 6 month follow up.

Brief Summary: Insomnia is very common in the elderly population and is associated with increased morbidity and a detrimental effect on quality of life. The main form of current therapy for insomnia is sedative-hypnotic drugs which can have serious negative side effects and cause adverse effects when used with alcohol or other medications. Thus there is an imperative to find other forms of safe and effective therapy for insomnia in the growing elderly population. Yoga includes a series of integrated activities that include physical exercises along with meditation, breathing and relaxation and these activities have previously been shown to influence psychophysiological, neuroendocrine, and autonomic parameters. Preliminary research suggests that yoga also provides benefit for people with insomnia but there is little rigorous research to confirm this and no research to determine if yoga or other forms of exercise can influence objective indicators of sleep or if it can be successfully adapted to an elderly population in Australia. This study primarily aims to examine the effectiveness of yoga as an intervention for geriatric insomnia and to determine the ability of yoga to enhance quality of life, mood and cognitive function. This study will build upon previous knowledge of yoga with a comprehensive 6-month, randomised, controlled trial of yoga for the treatment of insomnia in an elderly Australian population. The trial will involve 120 subjects randomized to either an integrated yoga intervention or a callisthenics control group. The study will aim to answer the following questions: 1. Does an integrated yoga intervention improve subjective and objective sleep quality and/or quality of life in elderly people with insomnia? 2. Does participation in yoga improve mood and/or cognitive function in elderly people with insomnia 3. Does participation in yoga reduce health resource utilization in elderly people with insomnia 4. Is yoga safe and acceptable for elderly people?

This study is a randomized controlled trial designed to assess the efficacy of Cognitive Existential Couples Therapy for men with early stage prostate cancer and their partners. Research has shown that men with early stage prostate cancer may experience considerable psychological distress in the months following their initial diagnosis. Research has also shown that their partners may also experience distress at the time of the diagnosis which, if left untreated, can lead to subsequent relationship difficulties. Cognitive Existential Couples Therapy has been designed to help couples cope in the aftermath of a prostate cancer diagnosis. It is predicted that couples who receive Cognitive Existential Couples Therapy will experience less psychological distress and show improved quality of relating and more adaptive coping compared to couples who receive medical treatment as usual.

All patients attending 2 dental practices for oral appliance therapy to treat obstructive sleep apnoea will be assessed for recruitment. Those who are able to sign informed consent will be enrolled. If a polysomnogram (PSG) has not been done, this will be done to confirm the apnoea hypopnoea index (AHI). Participants will be randomised to either usual care or usual care plus an apnealink study to evaluate treatment response. Should treatment response be inadequate as indicated by the ApneaLink in this group, further advancement of the mandible will be attempted. A repeat ApneaLink study will then be done and the process repeated. One month after titration is considered optimal, repeat PSG will be done. A repeat PSG will be done 1 month after optimal titration has been achieved in the control group. Secondary outcome measures of quality of life, symptoms and subjective sleepiness will be measured at baseline and at the time of the repeat PSG in both groups.

The purpose of this research is to compare the effect of the treatments (Tamoxifen and Exemestane) used in the main trial (TEXT-2) on bones. This will provide researchers and doctors with information as to whether these drugs are safe in terms of bone health and if there are increased or decreased risks of osteoporosis with the treatments. Approximately 200 patient's will be enrolled in this sub-study worldwide. Every patient will be in the sub-study for an average period of six years. However, participation in the study could be shorter depending on the response to the treatment on the main study.

Since the inception of human organ transplantation, HCMV remains single most-important cause of infectious morbidity and mortality in immunocompromised transplant patients. This project is designed to develop immunotherapeutic strategies based on adoptive transfer of virus- specific killer T cells for the treatment of HCMV infection in transplant patients. Who is it for? You can join this study if you have had an allogeneic haematopoietic stem cell transplant or a renal transplant at the Royal Brisbane Hospital and have a CMV infection. Trial details Blood will be collected from your stem cell donor (for SCT patients) or yourself and the CMV killer T cells grown in the laboratory (this takes about 3 weeks.) The cells are then tested for sterility and specificity. Once the cells pass these checks they will be infused into yourself: 4 doses at 2 weekly intervals and then a further 2 doses at 4 weekly intervals provided sufficient cells are produced. The effects of the treatment will be studied by monitoring your signs and symptoms and by blood tests. This will be done at the time of each treatment and then monthly for up to a year from the first treatment. Your total length of involvement will be no longer than 18 months.